GeoVax Labs Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 19

Employees

  • Stock Symbol
  • GOVX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.82
  • (As of Friday Closing)

GeoVax Labs General Information

Description

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Contact Information

Website
www.geovax.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1955 Lake Park Drive
  • Suite 300
  • Smyrna, GA 30080
  • United States
+1 (678)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1955 Lake Park Drive
  • Suite 300
  • Smyrna, GA 30080
  • United States
+1 (678)

GeoVax Labs Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeoVax Labs Stock Performance

As of 20-Nov-2026, GeoVax Labs’s stock price is $1.82. Its current market cap is $985K with 544K shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.82 $1.91 $1.50 - $270.66 $985K 544K 155K -$35.78

GeoVax Labs Financials Summary

As of 30-Sep-2026, GeoVax Labs has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 555 2,396 14,713 (3,051)
Revenue 0 2,489 3,955 0
EBITDA (18,280) (21,570) (25,049) (26,669)
Net Income (18,263) (21,465) (24,992) (25,967)
Total Assets 3,424 6,342 8,156 9,283
Total Debt 250 843 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeoVax Labs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeoVax Labs‘s full profile, request access.

Request a free trial

GeoVax Labs Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectio
Drug Discovery
Smyrna, GA
19 As of 2025

Wilmington, DE
 

Warminster, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GeoVax Labs Competitors (30)

One of GeoVax Labs’s 30 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Arbutus Biopharma Corporation Warminster, PA
Cytodyn Formerly Angel backed Vancouver, WA
Verastem Formerly VC-backed Needham, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 30 competitors. Get the full list »

GeoVax Labs Patents

GeoVax Labs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026085259-A1 Single-dose mva vaccines for protection against orthopoxvirus Pending 15-Oct-2024
WO-2024206243-A1 Pan-betacoronavirus vaccines and uses thereof Inactive 24-Mar-2023
AU-2022215566-A1 Viral constructs for use in enhancing t-cell priming during vaccination Pending 02-Feb-2021
AU-2022215566-A9 Viral constructs for use in enhancing t-cell priming during vaccination Pending 02-Feb-2021
CA-3206004-A1 Viral constructs for use in enhancing t-cell priming during vaccination Pending 02-Feb-2021 C12N15/86
To view GeoVax Labs’s complete patent history, request access »

GeoVax Labs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeoVax Labs Acquisitions (1)

GeoVax Labs’s most recent deal was a Merger/Acquisition with Dauphin Technology. The deal was made on 28-Sep-2006.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dauphin Technology 28-Sep-2006 Merger/Acquisition Computers, Parts and Peripherals
To view GeoVax Labs’s complete acquisitions history, request access »

GeoVax Labs ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.81 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view GeoVax Labs’s complete esg history, request access »

GeoVax Labs FAQs

  • When was GeoVax Labs founded?

    GeoVax Labs was founded in 2001.

  • Where is GeoVax Labs headquartered?

    GeoVax Labs is headquartered in Smyrna, GA.

  • What is the size of GeoVax Labs?

    GeoVax Labs has 19 total employees.

  • What industry is GeoVax Labs in?

    GeoVax Labs’s primary industry is Drug Discovery.

  • Is GeoVax Labs a private or public company?

    GeoVax Labs is a Public company.

  • What is GeoVax Labs’s stock symbol?

    The ticker symbol for GeoVax Labs is GOVX.

  • What is the current stock price of GeoVax Labs?

    As of 20-Nov-2026 the stock price of GeoVax Labs is $1.82.

  • What is the current market cap of GeoVax Labs?

    The current market capitalization of GeoVax Labs is $985K.

  • Who are GeoVax Labs’s competitors?

    Ayala Pharmaceuticals, Arbutus Biopharma, Cytodyn, Verastem, and Inovio Pharmaceuticals are some of the 30 competitors of GeoVax Labs.

  • What is GeoVax Labs’s annual earnings per share (EPS)?

    GeoVax Labs’s EPS for 12 months was -$35.78.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process